Psychiatr News March 3, 2006
Volume 41, Number 5, page 20
© 2006 American Psychiatric Association
Erratum
It was incorrectly reported in the January 20 issue that the
methylphenidate skin patch was deemed approvable by an FDA panel for the
treatment of attention-deficit/hyperactivity disorder in adults as well as
children aged 6 to 12. In fact, approval was sought and obtained for use only
in children aged 6 to 12. The patch was developed by Noven Pharmaceuticals and
will be marketed jointly by Noven and Shire Pharmaceuticals under the trade
name Daytrana. 
Get information about faster international access.
Privacy Policy
Copyright © 2006
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
